Evaluation of Benefit and Tolerability of IQP‐CL‐101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double‐Blinded, Randomised, Placebo‐Controlled Clinical Trial

• Published in: Phytotherapy research Vol. 31; no. 7; pp. 1056 - 1062
• Main Authors: Alt, Felix, Chong, Pee‐Win, Teng, Emily, Uebelhack, Ralf
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.07.2017; John Wiley and Sons Inc
• Subjects: Abdominal Pain - drug therapy; Adult; Biological Products - therapeutic use; Clinical trials; curcumin; Discomfort; Double-Blind Method; etiology; Female; Gastrointestinal Agents - therapeutic use; Herbal medicine; Humans; Intestine; IQP‐CL‐101; Irritable bowel syndrome; Irritable Bowel Syndrome - drug therapy; Male; Meals; Middle Aged; Pain; Patients; Pharmacology; Phytotherapy; placebos; Quality of Life; Treatment Outcome; Xanthofen; IQP-CL-101; Xanthofen; irritable bowel syndrome; curcumin
• ISSN: 0951-418X; 1099-1573; 1099-1573
• DOI: 10.1002/ptr.5826

Irritable bowel syndrome (IBS) is a functional bowel disorder of unknown aetiology. There is currently no known cure, and pharmacological interventions are usually targeting symptomatic relief, where natural and herbal remedies also play a role. This study aimed to evaluate the benefit and tolerability of IQP‐CL‐101 in symptomatic IBS relief. A double‐blinded, randomised, placebo‐controlled trial was conducted over 8 weeks. A total of 99 subjects fulfilling ROME‐III criteria for IBS were randomised into two groups, given either two IQP‐CL‐101 softgels or matching placebo twice daily before main meals. The primary endpoint was the difference in change of IBS Symptom Severity Score (IBS‐SSS) after an 8‐week intake of IQP‐CL‐101 compared to placebo. After 8 weeks, subjects on IQP‐CL‐101 showed a significant reduction in IBS‐SSS (113.0 ± 64.9‐point reduction) compared to subjects on placebo (38.7 ± 64.5‐point reduction) (p < 0.001). A significant improvement could be seen as early as 4 weeks. No serious adverse events were reported throughout. IQP‐CL‐101 can be considered beneficial in the improvement of IBS symptom severity, regardless of IBS type, and therefore able to improve quality of life in patients suffering from abdominal pain and discomfort. © 2017 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.